VYNE Therapeutics Inc. (NASDAQ:VYNE) Shares Sold by Parkman Healthcare Partners LLC

Parkman Healthcare Partners LLC trimmed its holdings in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) by 24.6% during the fourth quarter, Holdings Channel reports. The fund owned 152,973 shares of the company’s stock after selling 50,000 shares during the quarter. Parkman Healthcare Partners LLC’s holdings in VYNE Therapeutics were worth $512,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in shares of VYNE Therapeutics during the fourth quarter worth about $823,000. Bridgeway Capital Management LLC purchased a new stake in shares of VYNE Therapeutics during the fourth quarter worth about $124,000. Acorn Capital Advisors LLC purchased a new stake in shares of VYNE Therapeutics during the fourth quarter worth about $1,531,000. Jane Street Group LLC purchased a new stake in shares of VYNE Therapeutics during the fourth quarter worth about $68,000. Finally, Schonfeld Strategic Advisors LLC increased its holdings in VYNE Therapeutics by 4.8% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 176,658 shares of the company’s stock valued at $592,000 after buying an additional 8,058 shares during the last quarter. 83.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright lowered their price objective on VYNE Therapeutics from $5.75 to $4.50 and set a “buy” rating for the company in a report on Friday, April 25th.

VYNE Therapeutics Stock Up 4.8%

Shares of VYNE Therapeutics stock opened at $1.31 on Wednesday. The firm has a market cap of $19.93 million, a P/E ratio of -1.52 and a beta of 1.76. VYNE Therapeutics Inc. has a fifty-two week low of $1.18 and a fifty-two week high of $4.30. The business has a 50-day moving average price of $1.64 and a 200 day moving average price of $2.39.

VYNE Therapeutics (NASDAQ:VYNE) last posted its earnings results on Thursday, May 8th. The company reported ($0.20) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.09. The company had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.05 million. VYNE Therapeutics had a negative return on equity of 43.73% and a negative net margin of 6,896.55%. As a group, equities research analysts anticipate that VYNE Therapeutics Inc. will post -0.97 earnings per share for the current year.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.